Microfluidic Cell Arrays to Mimic 3D Tissue Microenvironment

Author(s):  
Zeynep Dereli-Korkut ◽  
Sihong Wang

We developed a functional high throughput 3D microfluidic living cell array (MLC) for anti-cancer drug screening and mechanism discovery. Contemporary drug screening methods suffer from low sample throughput and lack of abilities of mimicking the 3D microenvironment of mammalian tissues. The poor performance of anti-cancer drugs limits the efficacy at controlling the complex disease system like cancer. Systematic studies of apoptotic signaling pathways can be prominent approaches for searching active and effective treatments with less drug resistance. Hence, innovative bio-devices are needed to represent tumor microenvironment to understand the molecular signatures of apoptosis for testing new anticancer therapies targeting apoptosis. Our novel 3D MLC design is the prototype of a high-throughput drug screening platform targeting apoptotic signaling pathways.

2021 ◽  
Vol 11 (20) ◽  
pp. 9418
Author(s):  
Mojdeh Monjezi ◽  
Milad Rismanian ◽  
Hamidreza Jamaati ◽  
Navid Kashaninejad

The up-and-coming microfluidic technology is the most promising platform for designing anti-cancer drugs and new point-of-care diagnostics. Compared to conventional drug screening methods based on Petri dishes and animal studies, drug delivery in microfluidic systems has many advantages. For instance, these platforms offer high-throughput drug screening, require a small number of samples, provide an in vivo-like microenvironment for cells, and eliminate ethical issues associated with animal studies. Multiple cell cultures in microfluidic chips could better mimic the 3D tumor environment using low reagents consumption. The clinical experiments have shown that combinatorial drug treatments have a better therapeutic effect than monodrug therapy. Many attempts have been made in this field in the last decade. This review highlights the applications of microfluidic chips in anti-cancer drug screening and systematically categorizes these systems as a function of sample size and combination of drug screening. Finally, it provides a perspective on the future of the clinical applications of microfluidic systems for anti-cancer drug development.


Author(s):  
Mojdeh Monjezi ◽  
Milad Rismanian ◽  
Hamidreza Jamaati ◽  
Navid Kashaninejad

The up-and-coming microfluidic technology is the most promising platform for designing anti-cancer drugs and new point-of-care diagnostics. Compared to conventional drug screening methods based on Petri dishes and animal studies, drug delivery in microfluidic systems has many advantages. For instance, these platforms offer high throughput drug screening, require a small amount of samples, provide an in vivo-like microenvironment for cells, and eliminate ethical issues associated with animal studies. Multiple cell cultures in microfluidic chips could better mimic the 3D tumor environment using low reagents consumption. The clinical experiments have shown that combinatorial drug treatments have a better therapeutic effect than monodrug therapy. So many attempts were performed in this field in the last decade. This review highlights the applications of microfluidic chips in anti-cancer drug screening and systematically categorizes these systems as a function of sample size and combination of drug screening. Finally, it provides a perspective on the future of the clinical applications of microfluidic systems for anti-cancer drug development.


2019 ◽  
Vol 183 ◽  
pp. 108182 ◽  
Author(s):  
Wenguang Yang ◽  
Shuxiang Cai ◽  
Zheng Yuan ◽  
Youbin Lai ◽  
Haibo Yu ◽  
...  

2017 ◽  
Vol 40 (2) ◽  
pp. 427-435 ◽  
Author(s):  
Jianing Yang ◽  
Shengjun Zhao ◽  
Yunfei Ji ◽  
Lili Zhao ◽  
Qingzhu Kong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document